Lucas Siqueira Trindade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucas Siqueira Trindade has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alex Balduino
Cell Technology and Biology Lab Veiga de Almeida University Rio de Janeiro 20270‐150 RJ Brazil
1 shared publication - Dennis Daniel Taub
Veterans Administration Medical Center
1 shared publication - Eric Cordeiro-Spinetti
LaBioTeC, Universidade Veiga de Almeida Rio de Janeiro, Brazil
1 shared publication - Russell S. Taichman
Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry
1 shared publication - Wallace De Mello
Laboratory on Thymus Research, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
1 shared publication
Latest Publications
- Open Access
- 27 March 2014
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 2, 7
Human bone marrow mesenchymal progenitors: perspectives on an optimized in vitro manipulation
When it comes to regenerative medicine, mesenchymal stem cells (MSCs) are considered one of the most promising cell types for use in many cell therapies and bioengineering protocols. The International Society of Cellular Therapy recommended minimal criteria for defining multipotential MSC is based on adhesion and multipotency in vitro, and the presence or absence of select surface markers. Though these criteria help minimize discrepancies and allow some comparisons of data generated in different laboratories, the conditions in which cells are isolated and expanded are often not considered. Herein, we propose and recommend a few procedures to be followed to facilitate the establishment of quality control standards when working with mesenchymal progenitors isolation and expansion. Following these procedures, the classic Colony-Forming Unit-Fibroblast (CFU-f) assay is revisited and three major topics are considered to define conditions and to assist on protocol optimization and data interpretation. We envision that the creation of a guideline will help in the identification and isolation of long-term stem cells and short-term progenitors to better explore their regenerative potential for multiple therapeutic purposes.
- 27 March 2014
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 2, 7
Open AccessHuman bone marrow mesenchymal progenitors: perspectives on an optimized in vitro manipulation
When it comes to regenerative medicine, mesenchymal stem cells (MSCs) are considered one of the most promising cell types for use in many cell therapies and bioengineering protocols. The International Society of Cellular Therapy recommended minimal criteria for defining multipotential MSC is based on adhesion and multipotency in vitro, and the presence or absence of select surface markers. Though these criteria help minimize discrepancies and allow some comparisons of data generated in different laboratories, the conditions in which cells are isolated and expanded are often not considered. Herein, we propose and recommend a few procedures to be followed to facilitate the establishment of quality control standards when working with mesenchymal progenitors isolation and expansion. Following these procedures, the classic Colony-Forming Unit-Fibroblast (CFU-f) assay is revisited and three major topics are considered to define conditions and to assist on protocol optimization and data interpretation. We envision that the creation of a guideline will help in the identification and isolation of long-term stem cells and short-term progenitors to better explore their regenerative potential for multiple therapeutic purposes.